Engineered Immune-Cell Therapies for Restoring Immune Homeostasis After Prolonged Critical Illness

Abstract

Prolonged critical illness is frequently complicated by persistent immune dysregulation, manifesting as immune suppression, increased susceptibility to secondary infections, and impaired recovery. Recent advances in cellular engineering have enabled the development of immune-cell therapies aimed at restoring immune homeostasis in this vulnerable population. This review synthesizes evidence on the immunopathogenesis of prolonged critical illness, highlights clinical features and diagnostic approaches, and provides a comprehensive overview of engineered immune-cell therapies, including their mechanisms, clinical efficacy, safety, and guideline-based clinical recommendations. Emerging data suggest that rationally designed immune-cell products, such as chimeric antigen receptor (CAR)-modified T cells, regulatory T cells, and myeloid-derived suppressor cell modulators, hold promise for rebalancing immune responses and improving patient outcomes after prolonged critical illness.

Introduction

Critical illness, particularly when prolonged, exerts profound effects on immune function. The interplay of systemic inflammation, immune exhaustion, and secondary immune suppression underpins a spectrum of complications, including nosocomial infections, delayed organ recovery, and increased mortality. While supportive care has long been the mainstay, advances in immunology and cell engineering have ushered in a new era of targeted therapies. Engineered immune-cell therapies represent a paradigm shift in the management of immune dysregulation after critical illness, aiming not merely to suppress or stimulate, but to precisely restore immune homeostasis. As our understanding of the immune landscape in critical illness deepens, the clinical community faces both opportunities and challenges in translating these innovations to bedside practice.

Epidemiology / Disease Burden

Prolonged critical illness, defined as an intensive care unit (ICU) stay exceeding 7–14 days, affects approximately 5–10% of ICU admissions globally. Survivors of prolonged critical illness are at high risk of subsequent morbidity and mortality, with immune dysfunction accounting for a significant proportion of late ICU deaths. Studies indicate that up to 70% of these patients develop features of immunoparalysis, marked by lymphopenia, reduced HLA-DR expression on monocytes, and impaired cytokine responses. The burden extends beyond the acute phase, with increased incidence of secondary infections, sepsis, and chronic critical illness syndromes, posing substantial challenges for healthcare systems and families.

Pathophysiology

The immune response during and after critical illness is characterized by an initial hyperinflammatory phase, often termed "cytokine storm", followed by compensatory anti-inflammatory responses. In prolonged cases, this response may overshoot, resulting in immune exhaustion and sustained immunosuppression. Mechanistic studies have identified persistent lymphocyte apoptosis, expansion of regulatory T cells (Tregs), impaired antigen presentation, and the emergence of myeloid-derived suppressor cells (MDSCs) as key drivers of this dysregulated state. Disrupted balance between pro-inflammatory and regulatory pathways leaves patients vulnerable to opportunistic pathogens and impairs tissue repair mechanisms. The molecular underpinnings involve alterations in cytokine signaling, checkpoint molecule expression, and epigenetic reprogramming of immune cells.

Risk Factors

Multiple risk factors predispose patients to immune dysfunction after prolonged critical illness. These include advanced age, pre-existing comorbidities (such as diabetes, chronic kidney disease, or malignancy), high illness severity scores on admission, persistent organ dysfunction, and exposure to immunosuppressive medications (e.g., corticosteroids). Additionally, genetic predispositions influencing cytokine gene polymorphisms or HLA haplotypes have been implicated in modulating immune recovery trajectories. The cumulative burden of nosocomial infections, invasive devices, and repeated surgical interventions further compounds the risk.

Clinical Features

Clinically, immune dysregulation manifests as persistent or recurrent infections, delayed wound healing, non-resolving organ dysfunction, and, in some cases, features of secondary hemophagocytic lymphohistiocytosis. Laboratory findings may include lymphopenia, decreased monocyte HLA-DR expression, hypogammaglobulinemia, and elevated markers of inflammation (e.g., C-reactive protein, procalcitonin). A blunted response to recall antigens and vaccines is also frequently observed. Importantly, these features may overlap with other syndromes such as sepsis-associated immunosuppression and chronic critical illness, necessitating careful clinical evaluation.

Diagnosis

Diagnosis of immune dysregulation after prolonged critical illness involves a combination of clinical assessment and laboratory markers. Flow cytometric analysis of lymphocyte subsets, monocyte HLA-DR expression, and functional assays of cytokine production are increasingly utilized in research and select clinical settings. Emerging biomarkers, such as soluble PD-L1, IL-10, and specific gene expression signatures, are under investigation for their prognostic value. Risk stratification tools integrating clinical and immunological data are being developed to identify patients most likely to benefit from immune-modulating interventions.

Treatment & Management

Conventional management focuses on infection prevention, antimicrobial stewardship, nutritional support, and cautious use of immunosuppressive agents. However, these approaches often do not address the underlying immune dysregulation. Immune-stimulating agents, such as recombinant human interleukin-7 (IL-7) and granulocyte-macrophage colony-stimulating factor (GM-CSF), have shown promise in reversing lymphopenia and improving immune competence in select cohorts. Optimal supportive care, including early mobilization and rehabilitation, remains essential for holistic recovery.

Recent Advances / Emerging Therapies

Engineered immune-cell therapies represent a transformative approach to restoring immune homeostasis. CAR-modified T cells, although primarily developed for oncology, are being repurposed to target persistent viral or bacterial pathogens in immune-compromised patients. Regulatory T cell (Treg) infusions aim to recalibrate the immune system, mitigating both hyperinflammation and immunosuppression. Genetically engineered myeloid cells and MDSC modulators are under investigation to reverse antigen presentation deficits and enhance pathogen clearance. Clinical trials have demonstrated feasibility and early signals of efficacy, though concerns regarding safety, off-target effects, and optimal timing persist. Personalized cellular products, leveraging advances in single-cell profiling and CRISPR-based editing, are poised to refine therapeutic precision further.

Guideline Recommendations

International guidelines, including those from the Society of Critical Care Medicine and the European Society of Intensive Care Medicine, emphasize the importance of individualized immune monitoring in prolonged critical illness. While engineered immune-cell therapies remain investigational, their use is recommended within clinical trial settings or specialized centers with expertise in cellular immunotherapy. Guidance supports integrating immune profiling into routine assessment of high-risk patients and highlights the need for multidisciplinary collaboration in decision-making. Ongoing trials are expected to inform future updates and facilitate evidence-based adoption of these novel interventions.

Conclusion

Prolonged critical illness is frequently complicated by persistent immune dysregulation, contributing to adverse outcomes and challenging conventional management paradigms. Engineered immune-cell therapies offer a promising and mechanistically rational strategy for restoring immune homeostasis. While preliminary data are encouraging, further research is needed to define optimal indications, dosing, safety profiles, and integration into existing care pathways. As the field evolves, close collaboration between intensivists, immunologists, and cell therapy specialists will be vital to translating scientific advances into meaningful clinical benefit for critically ill patients.